Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide 1 . Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.
How this therapy could help:
The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques and tau tangles, abnormal protein deposits that build up in the brain and in the brain cells. BIIB080 (IONIS-MAPT Rx ) is an antisense oligonucleotide (ASO) that may reduce production of the tau protein and its accumulation in brain cells, potentially slowing the progress of the disease.
In 2003, Biogen merged with San Diego, California -based IDEC Pharmaceuticals (formed in 1986 by biotech pioneers Ivor Royston , Howard Birndorf and Robert E. Sobol) and adopted the name Biogen Idec. After the merger, Biogen Idec became the 3rd largest Biotechnology company in the world.  Following shifts in research core areas, the company has since shortened its name, reverting to simply Biogen.  Biogen stock is a component of several stock indices such as the S&P 100 , S&P 500 , S&P 1500 , and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB.